Attachment F

510(k) Summary and Certification

[As required by 21 CFR 807.92(c)]

1. **Submitter / Contact Person / Date of Preparation**

| Submitter          | Zyga Technology, Inc.  
|                    | 700 10th Ave South  
|                    | Minneapolis, MN  55415-1745  
| Contact Person     | Diane Brinza  
|                    | Director of Regulatory and Clinical  
|                    | Ph. 612.455.1061, ext. 104  
|                    | Fax. 612.455.1064  
| Date of Preparation | February 21, 2011  

2. **General Information**

| Trade Name          | Slmmetry™ Sacroiliac Joint Fusion System  
| Common / Usual Name | Fixation Device/Bone Screw  
| Classification Name | Smooth or threaded metallic bone fixation fastener  
| Classification      | Class II (per 21 CFR § 888.3040)  
| Manufacturer        | Zyga Technology, Inc.  
|                    | 700 10th Ave South  
|                    | Minneapolis, MN  55415-1745  
| Identification of Predicate Devices | K102907  
|                    | Zyga Technology, Inc.  
|                    | Slmmetry™ Sacroiliac Joint Fusion System  

Page __ of 2
## Zyga Technology, Inc.
Special 510(k) - Symmetry™ Sacroiliac Joint Fusion System Modification
February 21, 2011

<table>
<thead>
<tr>
<th>Device Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Symmetry™ Sacroiliac Joint Fusion System consists of cannulated screws available in titanium having diameters ranging from 6.5mm-12.5mm; and lengths of 30mm-70mm; titanium washers are available for the 6.5mm diameter screws. The revised surgical technique manual for the new modified version of the Symmetry™ Sacroiliac Joint Fusion System contain instructions for adding autologous graft material to the sacroiliac joint to help ensure fusion.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intended Use / Indications for Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Symmetry™ Sacroiliac Joint Fusion System is intended for fixation of large bones, including bones of the pelvis, for conditions including degenerative spondylitis and sacroiliac joint disruptions.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Technological Characteristic</th>
</tr>
</thead>
<tbody>
<tr>
<td>The principle of operation and fundamental scientific technology of the subject devices is identical to that of the identified predicate.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>The subject devices are manufactured from Titanium Alloy (Ti-6Al-4V ELI).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Technological Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>The modification of the Symmetry™ Sacroiliac Joint Fusion System does not represent a change in technological characteristics from that of the indicated predicate device, and therefore does not raise any new questions of safety or effectiveness.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Summary of Non-clinical Performance Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>The modification from the previous version of this device does not affect the intended use or alter the fundamental scientific technology or performance of the device when compared to the identified predicate. The addition of autologous graft material to the sacroiliac joint does not require testing to ensure substantial equivalence to the unmodified device.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equivalence for the Symmetry Sacroiliac Joint Fusion System is based on the same indications for use, design features, operational principles, and material composition and mechanical performance when compared to the predicate device cleared under K102907.</td>
</tr>
</tbody>
</table>
Dear Ms. Brinza:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act.
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson
Director
Division of Surgical, Orthopedic and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use Statement

510(k) Number (if known)

Device Name Symmetry Sacroiliac Joint Fusion System

Indications for Use
The Symmetry™ Sacroiliac Joint Fusion System is intended for fixation of large bones, including bones of the pelvis, for conditions including degenerative sacroiliitis and sacroiliac joint disruptions.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X OR Over-The-Counter Use
(Per 21 CFR 801.109)

510(k) Number K110512